No Data
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Plans to conclude the "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient product project" and permanently supplement working capital with the surplus fundraising.
On December 11, Gelonghui reported that Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that its fifth Board of Directors' eighteenth meeting and the fifth Supervisory Board's fourteenth meeting on December 11, 2024, reviewed and approved the proposal regarding the conclusion of the fundraising investment project and the permanent supplement of surplus raised funds to working capital, agreeing to conclude the fundraising investment project "Annual production of 35 tons of heparin series Active Pharmaceutical Ingredient products project" and permanently supplement the surplus raised funds to working capital.
Express News | The weight loss medication sector has seen some fluctuations, with hebei changshan biochemical pharmaceutical rising over 10%.
Express News | Five listed companies' stocks experienced significant shareholding by important shareholders, with hebei changshan biochemical pharmaceutical having the highest shareholding amount.
Hebei Changshan Biochemical Pharmaceutical (300255.SZ) shareholder Yang Minghuan completed a 1% shareholding reduction.
Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that it recently received a document from shareholder Mr. Yang Minghuan regarding the "..."
A-share pharmaceutical stocks fell, hebei changshan biochemical pharmaceutical dropped over 5%.
On November 22, Gelunhui: Tianxin Pharmaceutical, Zhejiang Shapuaisi Pharmaceutical, Shenzhen Chipscreen Biosciences, Hebei Changshan Biochemical Pharmaceutical fell more than 5%, fujian cosunter pharmaceutical, haisco pharmaceutical group, and China Resources Double-Crane Pharmaceutical followed suit.
Changshan Biochemical Pharma Shareholder Trims Stake
No Data
